IONQ Inc vs Relay Therapeutics Inc. Common Stock — how do they compare? IONQ Inc trades at $40.17 (market cap $15.98B), while Relay Therapeutics Inc. Common Stock trades at $17.59 (market cap $3.82B). The key difference: IONQ Inc is far larger — about 4.2× Relay Therapeutics Inc. Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| IONQ | RLAY | |
|---|---|---|
Market Cap | $15.98B | $3.82B |
Volume | 22,848,240 | 4,332,079 |
Sector | Technology | Health |
52-Week High | $82.09 | $20.75 |
52-Week Low | $26.59 | $6.03 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $13.92B | $2.93B |
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $41.34, down 4.5% today, with a mixed technical signal leaning bullish overall. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, reflecting high growth spending. Recent news highlights strong analyst backing, including Bank of America's Buy rating and $60 target, citing IonQ's trapped-ion quantum computing technology and partnerships.
Outlook: IonQ offers high growth potential in quantum computing, supported by bullish analyst targets averaging $62.75. Risks include persistent losses, cash burn, and intense competition. Investors should weigh the long-term disruptive potential against current profitability challenges and valuation premiums.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →